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ABSTRACT
Stat3 is constitutively activated in several tumor types and plays an essential role in maintaining their
malignant phenotype and immunosupression. To take advantage of the promising antitumor activity of
Stat3 targeting, it is vital to understand the mechanism by which Stat3 regulates both cell autonomous and
non-autonomous processes. Here, we demonstrated that turning off Stat3 constitutive activation in different
cancer cell types induces senescence, thus revealing their Stat3 addiction. Taking advantage of the senes-
cence-associated secretory phenotype (SASP) induced by Stat3 silencing (SASP-siStat3), we designed an
immunotherapy. The administration of SASP-siStat3 immunotherapy induced a strong inhibition of triple-
negative breast cancer andmelanoma growth associatedwith activation of CD4 + T and NK cells. Combining
this immunotherapy with anti-PD-1 antibody resulted in survival improvement in mice bearing melanoma.
The characterization of the SASP components revealed that type I IFN-related mediators, triggered by the
activation of the cyclic GMP-AMP synthase DNA sensing pathway, are important for its immunosurveillance
activity. Overall, our findings provided evidence that administration of SASP-siStat3 or low dose of Stat3-
blocking agents would benefit patients with Stat3-addicted tumors to unleash an antitumor immune
response and to improve the effectiveness of immune checkpoint inhibitors.
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Introduction
Stat3 has been recognized as an oncogene as its activation
promotes cellular transformation.1 Stat3 constitutive activation
contributes to cell survival, angiogenesis, and proliferation in
a large variety of cancer types.2,3 In addition, Stat3 also controls
innate and adaptive antitumor immune responses by the pro-
duction of immunosuppressive factors that exert a “feed-
forward” mechanism activating Stat3 in different immune cell
subtypes.4 Indeed, it drives the differentiation of myeloid-
derived suppressor cells (MDSCs) and regulatory T (Tregs)
cells and hampers NK cell activation and CD8 + T cell
cytoxicity.5,6 Conversely, blockade of Stat3 activation in cancer
cells induces an increase in pro-inflammatory mediators that
leads to antitumor immunity.4,7 In line with these findings, we
previously demonstrated that immunization with Stat3-blocked
breast cancer cells induces an antitumor immune response
involving CD4 + T and NK cells.8 However, the effect of Stat3
inhibition non-autonomous activity in vivo and the molecular
mechanism that regulates the production of cytokines/chemo-
kines able to reinstate immunosurveillance have not been
addressed.
We have previously shown that Stat3 blockade in murine
breast cancer models in vitro, induces cellular senescence.8
Cellular senescence is a stable cell growth arrest that can be
induced by replicative exhaustion, chemotherapy or radio-
therapy, or oncogenic stimuli, among others.9-12 Another
source of cellular senescence is related to oncogene addiction:
cancer cells frequently become “addicted to” the constitutive
activation or overexpression of a single oncogene to preserve
their malignant phenotype.13 Blockade of oncogene addiction
can reactivate cellular senescence, a process known as onco-
gene inhibition-induced senescence (OIIS).14 Senescent cells
produce a secretory profile composed mainly of growth fac-
tors, cytokines, and proteinases, a signature termed senes-
cence-associated secretory phenotype (SASP). The SASP can
either foster tumorigenesis or stimulate the innate and adap-
tive antitumor immune response, a process called senescence
immunosurveillance.15,16 Thus, we hypothesized that Stat3
blockade in cancer cells triggers an OIIS program able to
secrete mediators that induce senescence immunosurveillance.
In this work, we report that targeting Stat3 in Stat3-
addicted cancer cells turns them senescent and produces
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a SASP able to unleash an antitumor immune response
against established 4T1 murine triple-negative breast cancer
and B16 melanoma. This SASP overcomes melanoma resis-
tance to antiprogrammed cell death protein 1 (PD-1) anti-
body. We identify type I IFN-induced factors as the main
components responsible for the immunosurveillance proper-
ties of the SASP and disclose the underlying mechanism of
their production.
Materials and methods
Reagents and antibodies
Detailed information regarding the reagents and antibodies
used in this study is provided in Supplem. Table 1.
Animals and tumors
Experiments were carried out with virgin female BALB/c mice,
raised at the Institute of Biology and Experimental Medicine of
Buenos Aires and with male C57BL/6 purchased from The
Charles River Laboratories, and were maintained in pathogen-
free conditions. All animal studies were conducted in accordance
with the highest standards of animal care as outlined by the
National Institutes of Health’s Guide for the Care and Use of
Laboratory Animals and were approved by the Institute of
Biology and Experimental Medicine and Institute Curie Animal
Research Committee. Progestin-dependent ductal tumor line
C4HD was originated in mice treated with 40 mg medroxypro-
gesterone acetate (MPA; Gador) every 3 months for 1 year and
weremaintained by serial transplantation in animals treated with
40mg s.c. depot–MPA in the opposite flank to tumor inoculum.8
Cell lines and siRNA transfections
T-47D, BT-474, MDA-MB-468, MDA-MB-231, CT-26,
HuVEC, YAC-1, and NCI-N87 cells were obtained from the
American Type Culture Collection and JIMT-1 cells from the
German Resource Center for Biological Material. KPL-4 and
cells were kindly provided by Dr. J. Kurebayashi (Kawasaki
Medical School, Kurashiki, Japan). B16F10-OVA (B16) mela-
noma cell line was kindly provided by Dr. K. Rock (University of
Massachusetts Medical School, Boston, MA), and MCA101-
OVA (MCA101) was kindly provided by Dr. Clothilde Théry
(Institut Curie, PSL Research University INSERM U932, Paris,
France). Primary cultures of epithelial cells from C4HD tumors
growing in MPA treated mice were performed as described
previously.8 Experiments and cell maintenance were performed
in DMEM:F12 (1:1 v/v) or RPMI1640 medium (Life
Technologies) supplemented with 10% heat-inactivated fetal
bovine serum (FBS, Internegocios). Cells were routinely tested
for Mycoplasma contamination.
siRNAs were synthesized by Dharmacon. Experiments
were performed with at least two different siRNA sequences
for each protein, but we here presented results obtained with
only one of them. A control siRNA oligonucleotide from
Dharmacon that does not target any known mammalian
gene was used as a negative control. siRNAs were used at
a final concentration of 100 nmol/L and were transfected with
Dharmafect1 reagent for 48 h according to the manufacturer’s
specifications and as we previously described.17
Conditioned medium
4T1, B16, MCA101, and MDA-MB-231 cells plated in 100-
mm dishes were transiently transfected with the indicated
siRNA or treated with 100 mmol/L doxorubicin (Abbot,
Buenos Aires, Argentina). Then, cells were washed three
times with PBS and cultured for 24 h with serum-free med-
ium. After incubation, the conditioned medium (CM) was
collected and centrifuged at 400 g. This CM was mixed with
a complete medium in a proportion of 1 to 1 for in vitro
studies. For in vivo administration, CM was collected, filtered
through a 0.2-µm pore filter, concentrated with spin-columns
of 3kD cutoff (Merck Millipore) and lyophilized. The
lyophilized CM was embedded in Elvax particles (DuPont)18
and implanted s.c. as a pellet to the animals.
Tumor experiments
Immunization protocol: BALB/c mice or C57BL/6 animals
were injected s.c. with 1 × 104 4T1 or 1 × 105 B16 cells,
respectively. When tumors reached 50 mm3, animals were
immunized with 1 × 106 4T1 or B16 irradiated cells s.c.
Simultaneously, a pellet of CM-siStat3 or CM-siControl was
implanted s.c. This immunization was repeated three times
according to the detailed experimental condition. In the indi-
cated experiments, anti-PD-1 antibody (10 mg/kg) was admi-
nistered i.p. Animals were monitored, and tumor width (W)
and length (L) were measured with a Vernier caliper three
times a week and tumor volume (mm3) was calculated as (L ×
W2)/2. Endpoint criteria for the survival studies included
tumor volume exceeding 1000 mm3 or tumor ulceration.
Treatment with JSI-124: BALB/c or C57BL/6 animals was
injected s.c. with 1 × 104 4T1 or 1 × 105 B16 cells, respectively.
When tumors reached 100 mm3, animals were treated daily
with 1 mg/kg JSI-124 i.p. Animals were monitored, and the
tumor volume was measured three times a week.
Evaluation of pulmonary metastasis
BALB/c mice bearing 4T1 tumors were sacrificed, lungs were
fixed in Bouin solution, and the number of superficial lung
colonies was counted by an investigator who was blind to the
experimental arm.
Preparation of cell suspensions
Subcutaneous tumors were collected and cut into small pieces
and placed into 2.5 mL of CO2 independent medium (Gibco,
Thermo Fisher Scientific, Waltham, MA) containing 0.1 mg/
mL DNase I and 0.1 mg/ml Liberase TL. After mechanical
dissociation, samples were incubated with shaking at 37°C for
30 min. The cell suspension was then filtered with a 70-μm
cell strainer (BD Biosciences) for direct tumor cell analysis
and further separated on a Percoll gradient (GE Healthcare
Life Sciences) from 40% to 75% interface to recover mono-
nuclear cells for immune cell infiltrate analysis.
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Spleens were removed and dissected into small pieces and
single-cell suspensions were obtained by mechanical disrup-
tion. A red blood cell lysis (5 min, room temperature) was
performed using 1 ml ammonium–chloride–potassium lysis
buffer.
Flow cytometry
Surface staining was performed at 4°C with the indicated
antibodies resuspended in PBS with 2% FBS and 2 mM
EDTA. All intracellular staining was performed using intra-
cellular Fixation/Permeabilization buffer set (eBioscience/
Thermo Fisher) according to the manufacturer’s instructions.
Live-cell detection was performed using the Zombie Aqua
Fixable Viability Kit (Biolegend). Flow cytometry was per-
formed on an LSR Fortessa or Canto II flow cytometer (BD
Biosciences) and analyzed using FlowJo software (version 10x,
BD Biosciences).
NK cell degranulation assay
For degranulation evaluation, splenocytes were cultured alone
or with YAC-1 (1x104 cells) overnight at 37°C. During the last
4 h, CD107a antibody was added. Cells were harvested and
stained with CD3 and CD49b antibodies to gate NK cells
(CD3-CD49b+ cells) and to determine the percentage of
CD107a+ cells by flow cytometry.
Detection of Ag-specific T cells by Enzyme-Linked
ImmunoSpot Assay (ELISPOT)
IFNϒ-producing antigen-specific CD8 T cells were mea-
sured by ELISPOT. Briefly, microplates (MAIPS4510;
Merck Millipore) were coated with antimurine IFNϒ
(Diaclone). Peripheral blood mononuclear cells (0.3×106)
were cultured overnight in the presence of either control
medium or class I–restricted OVA-I peptide (257–264,
SIINFEKL, 10 mM). Cells and peptides were resuspended
in complete medium RPMI supplemented with 10% FBS,
2 mM L-glutamine (Life Technologies), 1% penicillin/strep-
tomycin (Life Technologies) and ß-mercaptoethanol.
Detection of IFNϒ-producing cells was performed with
biotinylated anti-IFNϒ (matched pairs; Diaclone) followed
by streptavidin–alkaline phosphatase (Mabtech) and
revealed using the appropriate substrate (Bio-Rad). Spots
were counted using an ELISPOT Reader System ELR02
(AID Diagnostika). Results were expressed as the number
of cytokine-producing cells per 1 × 106 of total cells.
Cytokine production
For detecting cytokine and chemokine secretion, the CM-
siStat3 and CM-siControl form 4T1 and B-16-OVA cells
were evaluated using Proteome Profiler Mouse XL Cytokine
Array developed according to the manufacturer’s protocol
(R&D Systems).
Evaluation of cytokine production (CXCL10, CCL2, CCL5,
IL-15, IL-1β, IL-6 and CXCL2) was quantified by sandwich
ELISA using paired cytokine-specific antibodies according to
the manufacturer’s instructions.
T cell activation and proliferation assays
Splenocytes were isolated from healthy BALB/c or C57BL/6
mice and T cells were purified by negative selection using
EasySep™ (Stemcell Technologies) Mouse T Cell Isolation Kit
according to the manufacturer’s specifications. For activation
and differentiation assay, T cells were stimulated with CD3/
CD28 beads (Gibco, Thermo Fisher Scientific) for 72 h in 96-
well plates using a 0.1:1 beads:lymphocyte ratio, and cells were
stained with the indicated antibodies. For proliferation assay,
stimulation with CD3/CD28 beads was performed for 72 h in
96-well plates using a 0.5:1 beads:lymphocyte ratio. In the last
6 h, a 0.5 μCi [3H] thymidine (NEN, DuPont; specific activity:
20 Ci/mmol) was added. The assay was performed by quad-
ruplicate as described previously.8 In some cases, antibodies
anti-CCL2, CCL5, CXCR3, IL-15, and IFNAR were added at
the beginning of the experiment.
C4HD, 4T1, MDA-MB-231, CT26, B16, MCA101, T-47D,
and HuVEC cells were culture during 48 h, and a pulse of 0.5
μCi [3H] thymidine was added in the last 16 h. In other set of
experiments, tumor cells were transfected with siRNA Stat3
with or without siRNA p21CIP1 or p16INK4a for 48 h.
Wound healing
A wound assay was employed to study the effect of CM-
siStat3 of tumor cell on its cell migration. Wounds 400 μm
wide were made in confluent monolayers. Cells were treated
with CM-siControl or CM-siStat3 obtained from the corre-
sponding cell line and allowed to migrate into the cell-free
area. At 18 h, cells were viewed and photographed with an
inverted Olympus CKX41 microscope with 10×/0.25 objective
using Olympus camera Q-Color 5. The cell-free wound area
was quantified using ImageJ software (National Institutes of
Health).
Sa-β-gal staining
Two methods were performed to assess the SA-β-gal activity
at pH 6.0. Transfected cells grown on glass coverslips or
frozen tumor tissues (10-μm thickness) mounted on slides
were washed in PBS, fixed in 3% formaldehyde, and washed
again in PBS and incubated 16 h at 37°C without CO2 with
fresh SA-β-gal staining solution: 1 mg/mL 5-bromo-4-chloro-
3-indolyl b-D-galactopyranoside (X-Gal) (Sigma Aldrich),
150 mM NaCl, 2 mM MgCl2, 40 mM citric acid/Na phosphate
buffer (pH 6), 5 mM potassium ferrocyanide, and 5 mM
potassium ferricyanide. The stained cells and tissues were
viewed and photographed with an inverted Olympus CKX41
microscope with 20X/0.4 objective using Olympus camera
Q-Color 5. For the second method, we used 5-dodecanoyla-
minofluorescein di-β-d-galactopyranoside, obtained from
Sigma-Aldrich as a substrate to detect SA-β-gal activity.
Briefly, cells grown on 12-well plates were pretreated with
100 nmol/L bafilomycin A1 (Sigma-Aldrich) for 1 h at 37°C
and 5% CO2 humidified environment and then were
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incubated with 33 μmol/L C12FDG for another 2 h. Cells were
washed with PBS and analyzed by flow cytometry with the
Canto II flow cytometer. The flow cytometry data were ana-
lyzed with FlowJo software.
Immunofluorescence detection of trimethyl K9 histone H3
Cells grown in glass coverslips were fixed and permeabilized
with ice-cold methanol and were then blocked in PBS 1%
bovine serum albumin (BSA). Trimethyl K9 histone H3 was
detected using a rabbit mAb (Merck Millipore), followed by
incubation with antirabbit IgG-Alexa 488 (Molecular Probes).
Negative controls were carried out using PBS instead of pri-
mary antibodies. Nuclei were detected by propidium iodide
(PI) staining (5 μg/ml). Cells were analyzed using a Nikon
Eclipse E800 confocal laser microscopy system using a 60x/1.4
oil immersion objective. Quantitative analysis of confocal
images was performed with ImageJ. We evaluated the inte-
grated fluorescence intensity value for Trimethyl K9 histone
H3 for 50 cells from each condition and obtained an average
value. The nuclear compartment was defined according to the
PI images. Fluorescence background (median) was subtracted
in all cases.
Western blot analysis
Cells were lysed in a buffer containing 50mM Tris (pH 7.4),
150mM NaCl, 1mM EDTA, 1mM EGTA, 10% glycerol, 1%
Nonidet P-40, 0.1% SDS, 1 mM Mg2Cl, 1 mM phenylmethyl-
sulfonylfluoride (PMSF), 10μg/ml leupeptin, 5 μg/ml pepsta-
tin, 5μg/ml aprotinin,1 mM sodium orthovanadate and 25mM
NaF. Lysates were centrifuged at 12,000 × g for 30 min at 4°C
and protein content in the supernatant was determined using
a Bradford Proteins were solubilized in sample buffer (60 mM
Tris–HCl, pH 6.8, 2% SDS, 10% glycerol, 0.7mM, 2β mercap-
toethanol, and 0.01% bromophenol blue) and subjected to
SDS-PAGE. Proteins were electroblotted onto nitrocellulose.
Membranes were immunoblotted with the antibodies shown
in Supplem. Table 1. Enhanced chemiluminescence was per-
formed according to the manufacturer’s instructions (GE
Healthcare). Signal intensities of phosphor-proteins were ana-
lyzed by densitometry using ImageJ software and normalized
to total protein bands. Experiments assessing total protein
content were also repeated three to five times and signal
intensities were normalized to β-tubulin bands, used as load-
ing control.
Proteomic studies
SILAC labeling, secretome collection 4T1 cells were cultured
for 8 passages in SILAC media Arg- and Lys-free DMEM
supplemented with “light” (12C6
14N2-Lys and
12C6
14N4-Arg)
or “heavy” (12C6
15N2 Lys and
12C6
15N4-Arg) isotopes. The
stable isotope labeling was confirmed by LC-MS/MS after
protein in-gel separation and digestion of blue bands.
4T1 cells labeled with “light” media were transfected with
Control siRNA and cells labeled with “heavy” media were
transfected with Stat3 siRNA. After 48 h of transfection,
cells were washed 5 times with PBS and cultured for another
24 h with serum-free medium.
For secretome collection, three secretomes of independent
experiments were collected (total volume: 5 mL/condition),
samples mixed in a 1:1 ratio and filtered through a 0.2 µm
syringe filter. Samples were concentrated to 500 µl using
centrifugal filtration units with 3 kD molecular weight cutoff.
Trypsin digestion Secretomes mixed at a 1:1 ratio were
analyzed after a combination of FASP and fractionation
through strong anion exchange separation. Ninety percent
of each secretome was diluted in 500 µL of 25 mM ammo-
nium bicarbonate before reduction with 5 mM dithiothreitol
at 37°C for 1 h and alkylation with 10-mM iodocacetamide
for 30 min at RT in the dark. Samples were then processed
by a FASP procedure using 3kD Nanosep devices (Pall),
according to standard protocols. Briefly, samples were
loaded into the filtration devices and centrifuged at 13,000
g for 25 min. 500 µL of 25-mM ammonium bicarbonate was
added and concentrated again. This step was repeated twice.
The resulting concentrate was diluted to 200 µL with 25-
mM ammonium bicarbonate and 2 µg trypsin/LysC was
added. After overnight incubation at RT, peptides were
collected by centrifugation of the filter units for 5 min.
Strong anion exchange separation-based fractionation of
peptides was performed as described.19 The six pH eluted
fractions were loaded onto a homemade C18 SepPak-packed
stage tip for desalting (principle by stacking one 3M Empore
SPE Extraction Disk Octadecyl (C18) and beads from
SepPak C18 Cartidge Waters into a 200-µL micropipette
tip). Desalted samples were reconstituted in injection buffer
(2% MeCN, 0.3% TFA) before LC-MS/MS analysis.
LC-MS/MS analysis Online LC was performed with an
RSLCnano system (Ultimate 3000, Thermo Scientific) coupled
online to an Orbitrap Fusion Tribrid mass spectrometer (MS,
Thermo Scientific). Peptides were trapped on a C18 column (75-
μm inner diameter × 2 cm; nanoViper Acclaim PepMapTM 100,
Thermo Scientific) with buffer A (2/98 MeCN/H2O in 0.1%
formic acid) at a flow rate of 4.0 µL/min over 4 min.
Separation was performed on a 50 cm × 75 μm C18 column
(nanoViper Acclaim PepMapTM RSLC, 2 μm, 100Å, Thermo
Scientific) regulated to a temperature of 55°C with a linear
gradient of 5% to 25% buffer B (100% MeCN in 0.1% formic
acid) at a flow rate of 300 nl/min over 100min. Full-scanMSwas
acquired in the Orbitrap analyzer with a resolution set to
120,000, and ions from each full scan were HCD fragmented
and analyzed in the linear ion trap.
Data Processing and Protein IdentificationData were searched
against the UniProtKB/Swiss-ProtMusmusculus database using
SequestHT through Thermo Scientific Proteome Discoverer (v
2.1). The mass tolerances in MS and MS/MS were set to 10 ppm
and 0.6 Da, respectively. We set carbamidomethyl cysteine,
oxidation of methionine, N-terminal acetylation, heavy 13C6
15
N2-Lysine (Lys8) and
13C6
15N4-Arginine (Arg10), medium
2H4-
Lysine (Lys4), and 13C6-Arginine (Arg6) as variable modifica-
tions. We set specificity of trypsin digestion and allowed two
missed cleavage sites.
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The resulting files were further processed by usingmyProMS (v
3.5).20 The Sequest HT target and decoy search result were vali-
dated at 1% false discovery rate with Percolator. For SILAC-based
protein quantification, peptides XICs (Extracted Ion
Chromatograms) were retrieved from Thermo Scientific
Proteome Discoverer. Global MAD normalization was applied
on the total signal to correct the XICs for each biological replicate
(n = 3). Protein ratios were computed as the geometrical mean of
related peptides. To estimate ratio significance, a t-test was per-
formedwith theRpackage limma21 and the false discovery rate has
been controlled, thanks to the Benjamini-Hochberg procedure22
with a threshold set to 0.05. (All quantified proteins have at least
two peptides quantified.) Data are available via ProteomeXchange
with identifier PXD013948.23 Secreted proteins were identified by
Secretome P and Signal P databases using “The Human Cancer
Secretome Database”24 and MetaSecKB (http://bioinformatics.
ysu.edu/secretomes/animal/index.php).
TCGA data preparation
RNA-seq, Microarray and iTRAQ expression datasets for
Breast Cancer were downloaded from TCGA25 using
TCGA-Assembler26,R27 software pipeline. Only primary
tumor samples were kept, for a total 1095 RNA-seq sam-
ples, 528 Microarray samples, and 105 iTRAQ samples. Out
of those 105 iTRAQ samples, 28 were discarded (77 were
kept) after a variance quality control.28 Data were then
normalized so that the expression had similar distributions
across samples.
Samples were classified into breast-cancer intrinsic sub-
types according to PAM50 molecular signature,29 using
PBCMC30 R package with 10000 permutations, a 0.01 signifi-
cance threshold, and a 0.1 correlation cutoff. To match TCGA
data with the protein annotation obtained from
myProMSoutput, MyGene.info31 annotation services were
used.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism 6.0. The identity of the statistical test performed,
p values and n values are stated in the figure legends.
Longitudinal tumor growth data were analyzed using two-
way ANOVA to assess overall group differences followed by
Tukey post hoc comparisons. Comparison of the number of
lung metastasis among different groups was done by the
nonparametric Mann–Whitney U test. Survival was ana-
lyzed using the Kaplan-Meier model and log-rank Mantel-
Cox test were used to compare two treatment groups.
Differential expression analysis between breast cancer
intrinsic subtypes in TCGA data was carried out using
limma R package21 between basal-like and the other sub-
types (Luminal A, Luminal B and Her2-enriched) and
p values were adjusted using Benjamini-Hochberg
procedure22 with a threshold set to 0.05. Parallelisms
between CM-siStat3 treatment and breast cancer subtypes
were studied through contingency tables and Pearson’s chi-
squared test. A p value < 0.05 was accepted as statistically
significant.
Results
Stat3 silencing induces senescence in Stat3-addicted
cancer cells
To investigate the underlying cancer cell characteristics that
dictate whether it can undergo senescence by Stat3 blockade,
we silenced Stat3 by siRNA transfection in several cancer cell
lines (Supplem. Figure 1(a)). Stat3 knockdown induced
a sharp rise in senescence-associated ß-galactosidase (SA-ß-
gal) activity and in heterochromatin formation trimethyl K9
histone H3, markers of cellular senescence,32,33 in HER2-
positive breast cancer cells, triple-negative breast cancer,
colon cancer, and melanoma (Figure 1(a) and Supplem.
Figure 1(b,c)). However, no modulation of SA-ß-gal was
observed in fibrosarcoma MCA101 cells and in the luminal
breast cancer BT-474 and T-47D cells (Figure 1(a) and
Supplem. Figure 1(b)). Strikingly, all cell lines that experi-
enced senescence after Stat3 knockdown had high levels of
Stat3 phosphorylation at Tyr705. In contrast, senescence was
absent in the cell lines in which Stat3 phosphorylation was
barely detected (Figure 1(b)). Proliferation of C4HD, 4T1,
MDA-MB-231, CT-26, and B16-OVA (hereafter abbreviated
B16) cells was largely decreased after Stat3 silencing; mean-
while, MCA101 and T-47D cell proliferation was not affected
(Figure 1(c)). Furthermore, senescence induced by Stat3
knockdown was dependent on the cyclin-dependent kinase
inhibitors p16INK4 or p21CIP1 (Supplem. Figure 1(d–f)).34
To study whether Stat3 inhibition-induced senescence
also takes place in vivo, mice bearing 4T1 or B16 tumors
were treated with the pharmacological inhibitor of Stat3
activation, JSI-124. Notably, the growth of both tumors
was greatly suppressed by JSI-124 treatment (Figure 1(d)).
The number of micrometastasis was decreased in mice
bearing 4T1 tumor treated with the Stat3 inhibitor vs con-
trol counterpart (Supplem. Figure 2(a)). We observed
strong SA-ß-gal staining, and blockade of Stat3 phosphor-
ylation in 4T1 and B16 tumors under JSI-124 treatment
(Figure 1(e) and Supplem. Figure 2(b)). Altogether, our
results demonstrate that Stat3 inhibition promotes
a senescence program in vitro and in vivo in cancer cells
that depend on Stat3 activation to maintain their malignant
phenotype, thus revealing that they are Stat3-addicted.
Therefore, Stat3 should be considered an oncogene whose
inactivation leads to OIIS, as it has been demonstrated for
MYC, RAS, and BCR-ABL1.35,36
SASP from Stat3-silenced cells has anti-tumor and
immune-stimulating activity in vitro
To evaluate the paracrine activity of the SASP induced by Stat3
silencing (SASP-siStat3) we used different cells of the tumor
microenvironment to perform functional assays. To test this,
we obtained the conditioned medium (CM) from 4T1, B16 and
MDA-MB-231 cells transfected with Stat3 siRNA (CM-siStat3)
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or with control siRNA (CM-siControl). CM from MCA101
cells that did not undergo senescence upon Stat3 silencing
(Figure 1(a)) was included as control. We observed that 4T1,
B16, and MDA-MB-231 cells cultured with CM-siStat3 exhib-
ited a decrease in proliferation and migration when compared
to cells cultured with CM-siControl (Figure 2(a,b), respec-
tively). When studying CM-siStat3 angiogenic potential, we
revealed that CM-siStat3 from 4T1, B16, and MDA-MB-231
cells do not increase HUVEC proliferation vs. CM-siControl
(Figure 2(c)). Finally, to investigate the immune-modulatory
activities of the SASP-siStat3, we performed functional assays of
murine T cells stimulated with anti-CD3/CD28-coated
beads. CM-siStat3 from 4T1 and B16 cells enhanced T cell
proliferation in comparison with CM-siControl (Figure 2(d)).
The CM-siStat3 from MCA101 cells showed similar behavior
than CM-siControl in the above-mentioned assays (Figure 2(a–
d)). As other control, we evaluated therapy-induced senescence
by doxorubicin treatment (Supplem. Figure 3(a,b)). The CM
from 4T1 and B16 cells treated with doxorubicin (CM-
Doxorubicin) did not modify CD3/CD28-induced T cell pro-
liferation vs control medium (Supplem. Figure 3(c)). Activation
of CD4 + T cells, determined by CD69 expression, increased in
the presence of CM-siStat3 vs CM-siControl from 4T1 and B16
cells (Figure 2(e)). In order to track the fate of naïve T cells
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exposed to CM-siStat3, CD62L, and CD44 expression was
determined. CM-siStat3 from 4T1 and B16 cells induced
a significant increase of effector cells, a decrease of naïve cells
and no change in central memory CD4 + T cell subpopulation
vs CM-siControl (Figure 2(f)). The CD8 + T cell subpopulation
analysis revealed a significantly skew toward central memory
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cells and away from naïve cells in CM-siStat3 vs CM-siControl
only from 4T1 cells (Figure 2(f)). Collectively, these results
indicate that the SASP-siStat3 has multiple paracrine antitumor
effect, impairing tumor cell proliferation, migration, and angio-
genic activity, while enhancing T cell proliferation and CD4 +
T cell differentiation to an effector phenotype.
SASP-siStat3 is an adjuvant for a cellular cancer
immunotherapy
The numerous in vitro antitumor effects of the SASP induced by
Stat3 silencing described above encouraged us to study its appli-
cation as a potential immunotherapy. Then, the CM-siStat3
and CM-siControl from 4T1 cells were concentrated, lyophi-
lized, and embedded in Elvax particles.18 We designed
a therapeutic administration protocol consisting of immuniza-
tions with wild type 4T1 irradiated tumor cells simultaneously
with the administration of CM-siStat3 (SASP-siStat3 immu-
notherapy) or CM-siControl (Figure 3(a)). In animals treated
with CM-siStat3, tumors grew strikingly more slowly and had
fewer lung metastases than in the CM-siControl group (Figure 3
(b,c)). CM-siStat3 immunized animals showed similar leukocyte
and T-cell tumor infiltration to the CM-siControl group (Figure
3(d)), but CM-siStat3 immunized animals showed an increased
percentage of effector CD4 + T cells (but not CD8 + T cells) in
tumor and spleen (Figure 3(e)). NK cells from CM-siStat3
immunized animals also showed an increase in activation, mea-
sured by CD69 staining, both in tumor and spleen, compared to
the CM-siControl group (Figure 3(f)). In regard to suppressor
immune cells, CM-siStat3 immunized animals exhibited
a significant decrease of Treg cell proportions in the tumor
(but not in the spleen) (Figure 3(g)). The presence of monocytic
MDSC (M-MDSC) was lower in the tumor of CM-siStat3
vs CM-siControl group, while for the granulocytic (MDSC)
G-MDSC population, a trend was observed (Figure 3(h)). The
antitumor effect of the SASP-siStat3 immunotherapy was depen-
dent on the concomitant presence of an antigen source, provided
by the irradiated cells, since the immunization with the CM-
siStat3 alone did not impact tumor growth (data not shown).
To evaluate the clinical applicability of the treatment, we
had analyzed the potential use of CM-siStat3 from cancer cells
as an universal preparation suitable for treating different
tumors. Thus, we injected 4T1 tumor-bearing mice with CM-
siStat3 from a different cell type, the melanoma B16 cells,
together with the irradiated 4T1 cells. Figure 3(j) shows
that CM-siStat3 from B16 decreases 4T1 tumor growth with
respect to animals treated with CM-siControl from B16.
These results suggest the CM-siStat3 from cancer cells can
have therapeutic potential.
We further evaluated the effectiveness of our immunotherapy
protocol in the B16 preclinical model (Figure 4(a)). We observed
a strong decrease of tumor growth in mice immunized with B16
irradiated cells and CM-siStat3 (Figure 4(b)) and an increase in
the survival of these mice (Figure 4(c)), when compared to CM-
siControl. To improve the efficacy of SASP-siStat3 immunother-
apy, we used the checkpoint blocking antibody against PD-1
(Figure 4(a)). Notably, anti-PD1 antibody plus the CM-siStat3
combination showed a trend toward suppressed B16 tumor
growth and synergistically improved mice survival with respect
to the CM-siStat3 alone (Figure 4(b,c)). In addition to the
experiments testing tumor growth (Figure 4(b)), tumor regres-
sion was only observed in the combination group (2 out of 12
animals). It is noteworthy that anti-PD-1 monotherapy did not
provide a measurable effect on survival or antitumor effect, nor
did its combination with CM-siControl (Figure 4(b,c)). In addi-
tion, PD-L1 levels did not change in B16 cells cultured with CM-
siStat3 with respect to CM-siControl (Supplem. Figure 4(a)).
Similar results were found in 4T1 cells and tumors (Supplem.
Figure 4(a,b)).
Administration of CM-siStat3 together with anti-PD1 anti-
body-induced antitumor specific CD8 + T cell response of about
fivefold compared to CM-siStat3, measured by IFN-γ produc-
tion (Figure 4(d)). The CM-Control+anti-PD-1 group tends to
have more IFN-γ production than CM-Control group making it
likely that anti-PD-1 might account for this effect. In addition,
the combination therapy revealed an influx in the tumor micro-
environment of leukocytes and T cells compared with the CM-
siStat3 alone and control groups (Figure 4(e)). In accordance
with the results obtained with 4T1 tumors, an increase in the
proportion of effector CD4 + T cells in tumor and spleen was
observed in the CM-siStat3 group, and this was in line with the
results obtained in vitro (Figure 2(f)). NK cells were also more
activated in the tumors and spleen of mice treated with CM-
siStat3 vs. CM-siControl (Figure 4(g)). The addition of anti-PD
-1 antibody to CM-siStat3 led to CD8 + T cell activation and
differentiation to an effector phenotype in the tumor and spleen
(Figure 4(f)). A decrease in Tregs infiltrating the tumor was also
evident in CM-siStat3 (Figure 4(h)). Addition of anti-PD-1 anti-
body did not further decrease tumor-infiltrating Tregs. These
data suggest that the SASP-siStat3 immunotherapy mobilized
and activated CD4 + T and NK cells and acted in synergy with
anti-PD-1 antibody, which, in turn, enhanced the expansion and
activation of tumor-specific CD8 + T cells to obtain tumor
clearance.
Then, we reasoned that combining a Stat3 inhibitor and PD-1
blockade could be another feasible antitumor strategy.
Considering the toxicity of the Stat3 inhibitors in the clinical
setting, we decided to administer JSI-124 every other day instead
of every day (Figure 1(d)) together with anti-PD-1; the latter at
the same dose as described in Figure 4b that showed to be
ineffective to control B16 tumor growth. We observed that JSI-
124 or anti-PD-1 alone has no antitumor effect. However, the
combination of JSI-124 and anti-PD-1 was able to significantly
inhibit B16 tumor growth (Figure 4(i)).
The SASP-siStat3 is enriched in chemokines and type
I IFN-associated genes
To characterize the immunomodulatory composition of the
SASP-siStat3, a multiplex membrane-based antibody array
was used. We observed that 11 and 7 molecules were upregu-
lated and 4 and 7 were downregulated in CM-siStat3 vs CM-
siControl from 4T1 and B16 cells, respectively (Figure 5(a)
and Supplem. Figure 5(a,b)). Among the downregulated cyto-
kines, we detected vascular endothelial growth factor (VEGF),
leukemia inhibitor factor (LIF) and regenerating islet-derived
protein 3-gamma (Reg3G), all Stat3-regulated genes (Figure 5
(a) and Supplem. Figure 5). In the repertoire of up-regulated
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Figure 3. Immunotherapy of SASP from Stat3-silenced 4T1 cells with irradiated wild type cells promotes an antitumor immune response.
(a) Immunotherapy protocol. BALB/c mice were challenged s.c. with 104 4T1 cells. When tumors were palpable, animals were injected s.c. with 106 irradiated 4T1 cells
(100 Gy) and with a depot containing the lyophilized CM-siControl or CM-siStat3 from 4T1 cells once a week for 3 weeks. Control group received PBS and irradiated
4T1 cells. Ten days after the last immunization, mice were sacrificed and the immune response was evaluated (n = 5 mice per group). (b) Tumor volume was
monitored along the experiment. (c) Lungs were harvested, fixed, and the number of 4T1 tumor nodules was counted. (d) Tumor-infiltrating leukocytes and T cells
were determined by CD45 and TCRß staining, respectively, and the number was referred to g tumor. (e) Effector CD4+ and CD8 + T cells were determined by CD44
and CD62L staining in tumor and spleen and analyzed by flow cytometry. (f) Intratumor and spleen NK cell activation was determined by staining with anti-CD69 on
the CD3-/DX5+ population. (g) The percentage of Tregs (FOXP3+/CD25+) from total CD4 + T cells of the tumor and spleen was determined by immunofluorescence
and analyzed by flow cytometry. (h) Tumor-infiltrating G-MDSC and M-MDSC populations were determined by Ly6C and Ly6G staining in the CD11b+ gate, and the
number was referred to g tumor. In spleen, both populations were referred to as percentage of CD45+ cells. (i) PD-L1 and PD-L2 expression levels of G-MDSC
and M-MDSC populations staining in tumor were analyzed by flow cytometry. (j) BALB/c mice were challenged s.c. with 104 4T1 cells. When tumors were palpable,
animals were injected s.c. with 106 irradiated 4T1 cells (100 Gy) and with a depot containing the lyophilized CM-siControl or CM-siStat3 from B16 cells once a week
for 2 weeks. Tumor volume was monitored (n = 5 mice per group). Data are presented as means ± SE. Data shown are representative of three independent
experiments b-i and of one experiment j. p values were calculated using two-way ANOVA test in b, j and two-tailed Student´s t test in c-i. *p < .05; **p < .01, ***p <
.001, ****p < .0001.
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Figure 4. Immunotherapy with SASP from Stat3-silenced cancer cells acts in synergy with anti-PD-1 antibodies.
(a) Immunotherapy protocol. C57BL/6 mice were challenged s.c. with 2 × 105 B16 cells. When tumors were palpable, animals were injected s.c. with 106 irradiated
B16 cells (100 Gy) and with a depot containing the lyophilized CM-siControl or CM-siStat3 from B16 cells every 5 days for 10 days. Three groups of animals received i.
p. anti-PD-1 antibodies (10 mg/kg) at the same time of the above-mentioned immunotherapy. Control group received PBS and irradiated B16 cells. (b) Tumor volume
was monitored along the experiment (n = 6 per group). (c) Survival curves exhibit differences of therapeutic efficacy of the immunotherapies in B16 melanoma.
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on the CD3-/NK1.1+ population and analyzed by flow cytometry. (h) Tregs from total CD4 + T-cells of the spleen and tumor were determined by immunofluor-
escence and analyzed by flow cytometry. (i) C57BL/6 mice were injected s.c. with 2 × 105 B16 cells. When tumors reached ~100 mm3 animals were injected i.p. with
1 mg/kg/day of JSI-124 (n = 5 mice per group) every other day, i.p. anti-PD-1 antibodies (10 mg/kg) on day 0 and 5 or both together. Control group was injected
with rat IgG. Tumor volume was monitored for 9 days. Data are presented as means ± SE. Data shown are representative of two independent experiments in b, d–g,
cumulative of two independent experiments in c and of one experiment in I. p values were calculated using two-way ANOVA test in b, i, log-rank Mantel–Cox test
comparing the two groups, in C and ANOVA with Tukey’s posttest in d–h. ns, not significant, *p < .05, **p < .01, ***p < .001, ****p< .0001.
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Figure 5. CCL2, CCL5, IL-15, and CXCL10 are mediators of the immune-stimulating activity of the SASP from Stat3-silenced cancer cells.
(a) CM-siControl and CM-siStat3 from 4T1 and B16 cells were analyzed using an antibody array for detecting cytokine and chemokine secretion. Heatmap of
differentially expressed proteins in CM-siStat3 vs. CM-siControl. (b,c) Determination of different cytokines and chemokines in CM-siControl and CM-siStat3 from 4T1,
B16, and MCA101 cells by ELISA. (d) Effect of neutralization of CXCR3, CCL2, CCL5, and IL-15 with specific antibodies on T cell proliferation. Purified T cells from spleen
of BALB/c mice were activated with CD3/CD28 beads in the presence of CM-siControl or CM-siStat3 from 4T1 cells for 48 h and the corresponding Armenian hamster
or goat control antibodies. In the case of CM-siStat3 different blocking antibodies were included. Data shown of CM-siControl and CM-siStat3 correspond to that
obtained with Armenian hamster antibody, yielding similar results to those from goat antibody (not shown). Similar protocols were followed with CM from B16 cells
but T cells were isolated from spleen of C57BL/6 mice. Proliferation was determined by [3H] thymidine incorporation at 72 h. Data are presented as means ± SE. Data
shown are representative of two (a, b), or three (c, d), independent experiments. p values were calculated using two-tailed Student´s t test in b, c and by ANOVA
with Tukey’s posttest in d. ns, not significant, *p < .05, **p < .01, ***p< .001, ****p < .0001.
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factors in CM-siStat3 from 4T1 and B16 cells we observed an
increase in IL-15 and the type I IFN-induced chemokines
CXCL10/interferon inducible protein 10, C-C motif chemo-
kine ligand 2 (CCL2) and CCL5 (Figure 5(a)), which are
potent T cell- and NK cell-activating cytokine/chemokines.37
These results were confirmed by ELISA, while these cytokine/
chemokine levels in CM-siStat3 from MCA101 cells were
similar to those obtained from CM-siControl (Figure 5(b)).
The hallmark of SASPs induced by Ras activation, irradiation,
or replicative senescence is the upregulation of IL-6, IL-1ß,
and CXCL2/macrophage inflammatory protein 2, the mouse
orthologous of human IL-8.38 The ELISA determination of IL-
1ß and IL-6 revealed that CM-siStat3 from 4T1, B16 and
MCA101 cells had the same levels of these proinflammatory
cytokines than CM-siControl (Figure 5(c)). CXCL2 levels
were downregulated in CM-siStat3 in 4T1 cells, and undetect-
able in B16 and MCA101 cells. On the other hand, the CM-
Doxorubicin exhibits an increase in CXCL10 in B16 cells and
of CCL5 and CXCL2 in 4T1 cells (Supplem. Figure 3(d)).
These data highlight the striking divergence of the SASP
induced by Stat3 silencing in contrast with senescence
induced by other types of insults.
To identify which cytokine/chemokine that emerged from
the antibody array studies mediates the senescence immu-
nosurveillance activity of the SASP-siStat3, we performed
neutralization assays on T cells stimulated with anti-CD3
/CD28-coated beads. Figure 5(d) shows that blockade of
CCL2, CCL5, IL-15 and CXCR3 (CXCL10 receptor) reduced
T cell proliferation exerted by CM-siStat3 from 4T1 and B16
cells compared to CM-siControl levels. These data suggest
that multiple factors secreted by Stat3-silenced cells promote
T cell proliferation.
We next sought to further decode the secreted proteins of
SASP-siStat3 by quantitative proteomic profiling using stable
isotope labeling of amino acids in cell culture (SILAC)-based
proteomics on CM-siControl and CM-siStat3 from 4T1 cells
(Supplem. Figure 6(a)). Among the 248 proteins found to be
differentially regulated (greater than or equal to two-log fold
change, p < .05) between CM-siStat3 and CM-siControl, 129
were upregulated and 119 were downregulated (Supplem.
Figure 6(a) and Supplem. Table 2). The clustergram obtained
using Wikipathway enrichment analysis on the upregulated
and downregulated proteins identified processes involved in
senescence and aging39,40 (Supplem. Figure 6(b)). Among the
downregulated proteins we also found Stat3 and Stat3-
regulated proteins such as CXCL1 (chemokine that recruits
neutrophils and promotes angiogenesis) and CYR61 (growth
and angiogenic factor) (Supplem. 6(b)), both proteins repre-
sented in the oncostatin/LIF signaling pathway.41
To further evaluate the clinical relevance of silencing Stat3,
we studied whether the modulated proteins obtained from
proteomic studies in CM-siControl compared to CM-siStat3
(CM-siStat3/CM-siControl) were also modulated in human
basal-like subtype compared to other breast cancer subtypes.
The comparison was centered in basal-like subtype because
60% of triple-negative breast carcinomas present that mole-
cular profile. The analysis was carried out retrieving RNA-seq,
Microarray and iTRAQ data from TCGA.25 We observed
a significant direct correlation between the up and
downregulated proteins in CM-siStat3/CM-siControl and
their transcriptomic (RNA-seq and Microarray) and proteo-
mic levels (iTRAQ) in luminal A/basal-like (Supplem. Figure
6(c)). Basal tumors stand out as aggressive and highly meta-
static, while luminal A tumors stand out as more benign,29
therefore the protein regulation observed in CM-siStat3 is
concordant to a shift toward a more benign phenotype.
The induction of senescence and of type I IFN response
induced by Stat3 silencing relies on cGAS
Most of the upregulated cytokines/chemokines found in the
SASP that have an important role in T cell proliferation belong
to the type I IFN response (Figure 5(d)). Indeed, proteomic
data using Reactome showed that the term “immune system”
was upregulated (P = .004) and IFN-induced protein 35 (IFI35)
and IFN-stimulated gene 15 (ISG15) were represented.42
Recently, it was demonstrated that chromatin fragments in
the cytosol of senescent cells trigger the cytosolic DNA sensor
cGAS, which produces the second messenger cyclic-
GMP–AMP that activates stimulator of interferon gene protein
(STING), thus engaging the production of inflammatory cyto-
kines, chemokines, and type I IFNs.43–47 Then, we studied the
potential contribution of cGAS on senescence induced by Stat3
silencing and on immunosurveillance characteristic of its SASP.
We observed that silencing cGAS did not affect senescence in
4T1 and B16 cells measured by 5-dodecanoylaminofluorescein
di-β-D-galactopyranoside staining (Figure 6(a)). Blockade of
cGAS expression completely inhibited senescence induced by
Stat3 silencing. Remarkably, the production of type I IFN-
related proteins, CXCL10, ISG15, and IFI35, produced by
Stat3 depletion, was greatly compromised in the absence of
cGAS (Figure 6(b,c)). Then, we observed that CM-siStat3+
sicGAS from 4T1 and B16 cells completely inhibited the
CD3/CD28 T cell proliferation exerted by CM-siStat3 (Figure
6(d)) suggesting the involvement of type I IFN-related proteins
in the stimulating activity in CM-siStat3. In addition, anti-IFN
alpha receptor antibodies inhibited the ability of CM-siStat3
from 4T1 and B16 cells to enhance T cell proliferation (Figure
6(e)). To study the contribution of cGAS pathway on the
antitumor immune response elicited by CM-siStat3, we went
back to the immunization protocol using 4T1 tumor model but
now including CM-siStat3+ sicGAS (Figure 6(f)). We observed
that the simultaneous depletion of cGAS and Stat3 in 4T1 cells
generates a CM that provides a partial protection from 4T1
tumor growth with respect to CM-siStat3 (Figure 6(g)).
The CM-sicGAS exhibited no antitumor effect (Figure 6(g)).
Together, these findings suggest that cGAS is a key player for
senescence and for the expression of inflammatory mediators
in Stat3-silenced senescent cells, thus implying its involvement
in the generation of immunosurveillance upon targeting Stat3.
Discussion
Stat3 has long been recognized as an attractive target in
oncology but, despite many efforts, chronic treatment of
solid tumors with Stat3 inhibitory drugs in humans faced
severe side effects. Therefore, to take advantage of the anti-
tumor activity of Stat3 blockade, it is key to understand the
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mechanism by which Stat3 regulates both cell autonomous
and non-autonomous processes, including host immunity.
Here, we disclose that inhibition of Stat3 in cancer cells
addicted to this oncogene induces cellular senescence and
generates a SASP that has two main antitumor properties:
one, linked to the downregulation of downstream targets of
Stat3 that promotes angiogenesis and tumorigenesis; and the
other, related to the up-regulation of mediators associated
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with the immunosurveillance properties of OIIS. Here, we
prove that the SASP-siStat3 immunotherapy is able to inhibit
breast cancer and melanoma growth and enhances the efficacy
of anti-PD-1 antibody. In addition, we uncover that the cGAS
DNA sensing pathway modulates the production of type I
IFN-inducible genes triggered by Stat3 inhibition thus reveal-
ing a mechanism of the immunosurveillance properties of the
SASP.
The SASP can have either pro or antitumor activities.15,48–51
Seminal works of Campisi´s lab described that SASP from human
fibroblast cell lines subjected to ionizing radiation, oxidative stress,
oncogenic RAS expression, or loss of p53, had the ability to induce
epithelial–mesenchymal transition and to stimulate invasion of
tumor cells. In addition, chemotherapy-induced senescence can
promote tumor clearance but the persistence of senescent cells can
cause chronic inflammation, drug resistance, cancer relapse, and
bone marrow suppression.52,53 Interestingly, tumor senescence
induced by radiation, chemotherapy, and HER2 activation
among others, has Stat3 activation as a hallmark, and Stat3-
driven cytokines are the main mediators of the SASP with protu-
morigenic activity.51,54,55 In contrast, here we targeted Stat3 and
observed a strong downregulation of LIF, CXCL2, Reg3G, and
VEGF, thus obtaining a SASP with a completely different compo-
sition from that described under the above-mentioned insults.
Toso and colleagues demonstrated that the SASP of Pten-
deficient prostate tumors has a protumorigenic and chemoresis-
tant activity due to constitutive activation of the Jak2/Stat3
pathway.56 In line with our findings, they “reprogramed” this
SASP phenotype by blocking Jak2, and observed tumor regression
when docetaxel was simultaneously administrated.56 Based on
these findings and our results, Stat3 inhibition could be an attrac-
tive strategy to reprogram the negative effects of the SASP induced
by different insults. Our results highlight the potential translat-
ability of the administration of CM-Stat3 from tumor cells in
combination with radiotherapy, as well as low dose of Stat3
inhibitors together with anti-PD-1 strategies in the oncology
arena. The observation that CM-siStat3 from B16 cells inhibits
4T1 tumor growth confirmed our previous data where we demon-
strated that immunization with irradiated 4T1 cells transfected
with a dominant negative plasmid of Stat3 (Stat3Y705F) inhibited
CT-26 (colon cancer) and C4HD (ErbB-2+ breast cancer) tumor
growth.8 These data suggest that a “universal” CM could be
obtained or formulated from Stat3-addicted tumors. In particular,
the application of clinical grade CM is an active field of research in
the area of regenerative medicine. A phase I trial based on admin-
istration of CM frommesenchymal stromal stem cells in multiple
sclerosis proved to be safe.57
The SASP from OIIS has been poorly explored. Data
available show upregulation of the antitumor factors IFN-
γ, TNFα, eotaxin, IL-5, and CCL5 and downregulation of the
protumoral factors IL-6 and VEGF, in Myc-inactivated
T-cell acute lymphoblastic lymphoma grown in immuno-
competent animals.49 The secretion of the above-
mentioned cytokines and chemokines relied on the presence
of CD4 + T cells, and tumor clearance was dependent on NK
cell activity.49 In agreement with this report, we have pre-
viously demonstrated that immunization with irradiated
Stat3-blocked tumor cells triggers an antitumor immune
response dependent on CD4 + T and NK cells.8 Here, we re-
create a similar antitumor immune response by using the
SASP-siStat3 immunotherapy. Neutralization of CXCR3,
CCL2, CCL5, and IL-15 proves that all these cytokines/
chemokines are required for the enhanced activity of the
SASP on T cell proliferation. Recently, it has been described
that the novel cytokine-like 1a (CYTL1) overexpression
reduces spontaneous lung metastasis reducing Stat3 phos-
phorylation in 4T1 tumor and in the lung tissue.58 These
findings lead to another strategy feasible to block Stat3.
Interestingly, proteomic studies of the SASP also reveal the
upregulation of the type I IFN-regulated genes IFI35 and
ISG15. It has already been described that Stat3 inhibition in
cancer cells upregulates type I IFN improving
immunosurveillance.4,59 In particular, Yang and colleagues
reported that type I IFNs were involved in the antitumor
effect of a combined therapy of Stat3 inhibitors and
chemotherapy.59
Additionally, senescent cells have aberrant cytosolic chroma-
tin fragments that trigger innate DNA recognition and induce
type I IFN production through the activation of the cGAS–
STING pathway.43-47 Our current work refines this scenario by
including cGAS as one of the principal mediators of OIIS, the
production of cytokines and chemokines and the antitumor
effect of the CM of cancer cells upon Stat3 silencing. The knowl-
edge of the interaction of PD-1 with PD-L1 activates a critical
immune checkpoint leading to T cell inhibition has been
exploited by the therapeutic intervention of antibodies against
PD-1 or PD-L1.60-62 However, the clinical effectiveness of these
antibodies relies on the presence of a T cell-infiltrated tumor
microenvironment.63 Our results obtained in the melanoma
model unveil a novel therapeutic strategy for tumors with poor
immune cell infiltration, by combining SASP-siStat3 immu-
notherapy with anti-PD-1 antibodies. We demonstrate that the
SASP-siStat3 contains chemokines able to recruit T cells and
activate T and NK cells in the tumor bed, allowing the anti-PD-1
effect.
Our findings highlight that Stat3 addiction confers vulner-
abilities to cancer cells and that targeting Stat3 triggers
a senescence program that unleashes an antitumor immune
response mediated by its SASP. This can open a potential
clinical application of our findings, through stratification of
tumors by Stat3 activation levels. Cancer patients with con-
stitutive activation of Stat3 are candidates for a short-term
treatment with Stat3-blocking strategies prior to or along with
immune checkpoint inhibitors.
Acknowledgments
We thank A. Molinolo (UCSD, San Diego, CA) for his constant help and
the mouse facility, mass spectrometry platform, and flow cytometry core
from Institut Curie. We are grateful for V. Chiauzzi´s technical assis-
tance. G. González from Radiation Oncology SA, Buenos Aires,
Argentina, is acknowledged for his expert support in cell irradiation.
We are grateful to Fundación René Baron and Fundación Williams for
their institutional support to IBYME-CONICET.
Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.
e1715767-14 M. DE MARTINO ET AL.
Funding
This work was supported by grants from National Cancer Institute
(Argentina) 2018, IDB/PICT 2017-1517 from the National Agency of
Scientific Promotion of Argentina (ANPCyT), Florencio Fiorini
Foundation and Alberto J. Roemmers Foundation awarded to RS;
a grant from Oncomed-Reno, CONICET 1819/03, awarded to PVE and
RS; grants from National Cancer Institute (Argentina) 2018, IDB/PICT
2015-1587, IDB/PICT 2017-1587, from ANPCyT, PID 2012-066 from
Consejo Nacional de Investigaciones Científicas y Tecnicas and from the
National Institute of Cancer from Argentina (Argentina) 2018-2019, all
of them awarded to PVE; IDB/PICT 2017-1770 grant from ANPCyT
awarded to CJP, grants from “Région Ile-de-France” and Fondation pour
la Recherche Médicale to DL, grants from Institute Curie, Institut
National de la Santé et de la Recherche Médicale, Association pour la
Recherche sur le Cancer (ARC PJA 20131200444); Labex DCBIOL
(ANR-10-IDEX-0001-02 PSL and ANR-11-LABX0043), SIRIC INCa-
DGOS-Inserm_12554 awarded to EP.
ORCID
Mara De Martino http://orcid.org/0000-0002-3049-6495
Mercedes Tkach http://orcid.org/0000-0002-8011-9444
Sofía Bruni http://orcid.org/0000-0001-7429-8039
Cecilia J. Proietti http://orcid.org/0000-0001-5875-4540
Florent Dingli http://orcid.org/0000-0002-7715-2446
Damarys Loew http://orcid.org/0000-0002-9111-8842
Patricia V. Elizalde http://orcid.org/0000-0002-5923-9898
Eliane Piaggio http://orcid.org/0000-0002-2455-8442
Roxana Schillaci http://orcid.org/0000-0002-7776-3378
References
1. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG,
Albanese C, Darnell JE Jr. Stat3 as an oncogene. Cell.
1999;98:295–303. doi:10.1016/S0092-8674(00)81959-5.
2. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis.
Oncogene. 2000;19:2474–2488. doi:10.1038/sj.onc.1203527.
3. Proietti CJ, Izzo F, Diaz Flaque MC, Cordo RR, Venturutti L,
Mercogliano MF, De Martino M, Pineda V, Munoz S, Guzman P,
et al. Heregulin co-opts PR transcriptional action via Stat3 role as
a coregulator to drive cancer growth. Mol Endocrinol.
2015;29:1468–1485. doi:10.1210/me.2015-1170.
4. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S,
Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al.
Regulation of the innate and adaptive immune responses by Stat-3
signaling in tumor cells. Nat Med. 2004;10:48–54. doi:10.1038/nm976.
5. Vasquez-Dunddel D, Pan F, Zeng Q, GorbounovM, Albesiano E, Fu J,
Blosser RL, Tam AJ, Bruno T, Zhang H, et al. STAT3 regulates
arginase-I in myeloid-derived suppressor cells from cancer patients.
J Clin Invest. 2013;123:1580–1589. doi:10.1172/JCI60083.
6. Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V,
Strobl B, Muller M, Sexl V. Loss of STAT3 in murine NK cells
enhances NK cell-dependent tumor surveillance. Blood.
2014;124:2370–2379. doi:10.1182/blood-2014-03-564450.
7. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and
immune cells: role of STAT3 in the tumour microenvironment.
Nat Rev Immunol. 2007;7:41–51. doi:10.1038/nri1995.
8. Tkach M, Coria L, Rosemblit C, Rivas MA, Proietti CJ, Diaz
Flaque MC, Beguelin W, Frahm I, Charreau EH, Cassataro J,
et al. Targeting Stat3 induces senescence in tumor cells and elicits
prophylactic and therapeutic immune responses against breast
cancer growth mediated by NK cells and CD4+ T cells.
J Immunol. 2012;189:1162–1172. doi:10.4049/jimmunol.1102538.
9. Johnson LM, Price DK, Figg WD. Treatment-induced secretion of
WNT16B promotes tumor growth and acquired resistance to che-
motherapy: implications for potential use of inhibitors in cancer
treatment. Cancer Biol Ther. 2013;14:90–91. doi:10.4161/cbt.22636.
10. Jones KR, Elmore LW, Jackson-Cook C, Demasters G, Povirk LF,
Holt SE, Gewirtz DA. p53-Dependent accelerated senescence
induced by ionizing radiation in breast tumour cells. Int J Radiat
Biol. 2005;81:445–458. doi:10.1080/09553000500168549.
11. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW.
Oncogenic ras provokes premature cell senescence associated
with accumulation of p53 and p16INK4a. Cell. 1997;88:593–602.
doi:10.1016/S0092-8674(00)81902-9.
12. Hayflick L. The limited in vitro lifetime of human diploid cell strains.
Exp Cell Res. 1965;37:614–636. doi:10.1016/0014-4827(65)90211-9.
13. Weinstein IB. Cancer. Addiction to oncogenes–the achilles heal of
cancer. Science. 2002;297:63–64. doi:10.1126/science.1073096.
14. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in
hematopoietic lineages. Mol Cell. 1999;4:199–207. doi:10.1016/
S1097-2765(00)80367-6.
15. Xue W, Zender L, Miething C, Dickins RA, Hernando E,
Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and
tumour clearance is triggered by p53 restoration in murine liver
carcinomas. Nature. 2007;445:656–660. doi:10.1038/nature05529.
16. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D,
Hohmeyer A, Gereke M, Rudalska R, Potapova A, et al. Senescence
surveillance of pre-malignant hepatocytes limits liver cancer
development. Nature. 2011;479:547–551. doi:10.1038/nature10599.
17. Mercogliano MF, De Martino M, Venturutti L, Rivas MA,
Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Deza EG,
Ares S, et al. TNFalpha-induced mucin 4 expression elicits tras-
tuzumab resistance in HER2-positive breast cancer. Clin Cancer
Res. 2017;23:636–648. doi:10.1158/1078-0432.CCR-16-0970.
18. Kumamoto T, Huang EK, Paek HJ, Morita A, Matsue H,
Valentini RF, Takashima A. Induction of tumor-specific protec-
tive immunity by in situ langerhans cell vaccine. Nat Biotechnol.
2002;20:64–69. doi:10.1038/nbt0102-64.
19. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal
sample preparation method for proteome analysis. Nat Methods.
2009;6:359–362. doi:10.1038/nmeth.1322.
20. Poullet P, Carpentier S, Barillot E. myProMS, a web server for
management and validation of mass spectrometry-based proteomic
data. Proteomics. 2007;7:2553–2556. doi:10.1002/pmic.200600784.
21. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK.
limma powers differential expression analyses for
RNA-sequencing and microarray studies. Nucleic Acids Res.
2015;43:e47. doi:10.1093/nar/gkv007.
22. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling
the false discovery rate in behavior genetics research. Behav Brain
Res. 2001;125:279–284. doi:10.1016/s0166-4328(01)00297-2.
23. Vizcaino JA, Csordas A, Del Toro N, Dianes JA, Griss J, Lavidas I,
Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, et al. update of
the PRIDE database and its related tools. Nucleic Acids Res.
2016;44:11033. doi:10.1093/nar/gkv1145.
24. Feizi A, Banaei-Esfahani A, Nielsen J. HCSD: the human cancer
secretome database. Database. 2015. doi:10.1093/database/bav051.
25. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C, Stuart JM. The cancer genome
atlas pan-cancer analysis project. Nat Genet. 2013;45:1113–1120.
doi:10.1038/ng.2764.
26. Wei L, Jin Z, Yang S, Xu Y, Y Z, Ji Y. TCGA-assembler 2: software
pipeline for retrieval and processing of TCGA/CPTAC data.
Bioinformatics. 2018;34:1615–1617. doi:10.1093/bioinformatics/btx812.
27. R: A Language and Environment for Statistical Computing. R Core
Team organization = R Foundation for Statistical Computing. Vienna,
Austria; 2018. https://www.R-project.org/
28. Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR,
Wang P, Wang X, Qiao JW, Cao S, Petralia F, et al.
Proteogenomics connects somatic mutations to signalling in
breast cancer. Nature. 2016;534:55–62. doi:10.1038/nature18003.
29. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T,
Davies S, Fauron C, He X, Hu Z, et al. Supervised risk predictor of
breast cancer based on intrinsic subtypes. J Clin Oncol.
2009;27:1160–1167. doi:10.1200/JCO.2008.18.1370.
ONCOIMMUNOLOGY e1715767-15
30. Fresno C, Gonzalez GA, Merino GA, Flesia AG, Podhjacer OL,
Llera AS, Fernández E. A novel non-parametric method for
uncertainty evaluation of correlation-based molecular signatures:
its application on PAM50 algorithm. Bioinformatics.
2017;33:693–700. doi:10.1093/bioinformatics/btw704.
31. Xin J, Mark A, Afrasiabi C, Tsueng G, Juchler M, Gopal N, Stupp GS,
Putman TE, Ainscough BJ, Griffith OL, et al. High-performance web
services for querying gene and variant annotation. Genome Biol.
2016;17(1):1–7. doi:10.1186/s13059-016-0953-9.
32. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C,
Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al.
A biomarker that identifies senescent human cells in culture and
in aging skin in vivo. Proc Natl Acad Sci U S A.
1995;92:9363–9367. doi:10.1073/pnas.92.20.9363.
33. NaritaM,Nunez S,Heard E,NaritaM, LinAW,Hearn SA, SpectorDL,
Hannon GJ, Lowe SW. Rb-mediated heterochromatin formation and
silencing of E2F target genes during cellular senescence. Cell.
2003;113:703–716. doi:10.1016/S0092-8674(03)00401-X.
34. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al Regaiey K,
Su L, Sharpless NE. Ink4a/Arf expression is a biomarker of aging. J Clin
Invest. 2004;114:1299–1307. doi:10.1172/JCI22475.
35. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M,
Sundberg CD, Bishop JM, Felsher DW. Sustained loss of
a neoplastic phenotype by brief inactivation of MYC. Science.
2002;297:102–104. doi:10.1126/science.1071489.
36. Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM,
Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C,
Jarpe M, et al. HDAC1,2 inhibition and doxorubicin impair
Mre11-dependent DNA repair and DISC to override BCR-ABL1-
driven DSB repair in Philadelphia chromosome-positive B-cell
precursor acute lymphoblastic leukemia. Leukemia.
2018;32:49–60. doi:10.1038/leu.2017.174.
37. Rauch I, Muller M, Decker T. The regulation of inflammation by
interferons and their STATs. JAKSTAT. 2013;2:e23820.
doi:10.4161/jkst.23820.
38. Freund A, Orjalo AV, Desprez PY, Campisi J. Inflammatory net-
works during cellular senescence: causes and consequences. Trends
Mol Med. 2010;16:238–246. doi:10.1016/j.molmed.2010.03.003.
39. Hernandez-Segura A, de Jong TV, Melov S, Guryev V, Campisi J,
Demaria M. Unmasking transcriptional heterogeneity in senescent
cells. Curr Biol. 2017;27:2652–2660. doi:10.1016/j.cub.2017.07.033.
40. Uthus EO, Brown-Borg HM. Altered methionine metabolism in
long living Ames dwarf mice. Exp Gerontol. 2003;38:491–498.
doi:10.1016/S0531-5565(03)00008-1.
41. Chen Y, Du XY. Functional properties and intracellular signaling of
CCN1/Cyr61. J Cell Biochem. 2007;100:1337–1345. doi:10.1002/
jcb.21194.
42. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM,
Silverman RH, Williams BR. Functional classification of
interferon-stimulated genes identified using microarrays.
J Leukoc Biol. 2001;69:912–920. doi:10.1189/jlb.69.6.912.
43. Yang H, Wang H, Ren J, Chen Q, Chen ZJ. cGAS is essential for
cellular senescence. Proc Natl Acad Sci U S A. 2017;114:E4612–
E4620. doi:10.1073/pnas.1705499114.
44. Dou Z, Ghosh K, Vizioli MG, Zhu J, Sen P, Wangensteen KJ,
Simithy J, Lan Y, Lin Y, Zhou Z, et al. Cytoplasmic chromatin
triggers inflammation in senescence and cancer. Nature.
2017;550:402–406. doi:10.1038/nature24050.
45. Gluck S, Guey B, Gulen MF, Wolter K, Kang TW, Schmacke NA,
Bridgeman A, Rehwinkel J, Zender L, Ablasser A. Innate immune
sensing of cytosolic chromatin fragments through cGAS promotes
senescence. Nat Cell Biol. 2017;19:1061–1070. doi:10.1038/ncb3586.
46. Galluzzi L, Vanpouille-Box C, Bakhoum SF, Demaria S. SnapShot:
CGAS-STING Signaling. Cell. 2018;173:276. doi:10.1016/j.
cell.2018.03.015.
47. Vanpouille-Box C, Demaria S, Formenti SC, Galluzzi L. Cytosolic
DNA sensing in organismal tumor control. Cancer Cell.
2018;34:361–378. doi:10.1016/j.ccell.2018.05.013.
48. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J,
Nelson PS, Desprez PY, Campisi J. Senescence-associated
secretory phenotypes reveal cell-nonautonomous functions of
oncogenic RAS and the p53 tumor suppressor. PLoS Biol.
2008;6:2853–2868. doi:10.1371/journal.pbio.0060301.
49. Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A,
Fan AC, Yang Q, Braunstein L, Crosby E, et al. CD4(+) T cells
contribute to the remodeling of the microenvironment required for
sustained tumor regression upon oncogene inactivation. Cancer Cell.
2010;18:485–498. doi:10.1016/j.ccr.2010.10.002.
50. Liu D, Hornsby PJ. Senescent human fibroblasts increase the early
growth of xenograft tumors via matrix metalloproteinase
secretion. Cancer Res. 2007;67:3117–3126. doi:10.1158/0008-
5472.CAN-06-3452.
51. Zacarias-Fluck MF, Morancho B, Vicario R, Luque GA,
Escorihuela M, Villanueva J, Rubio IT, Arribas J. Effect of cellular
senescence on the growth of HER2-positive breast cancers. J Natl
Cancer Inst. 2015:107. doi:10.1093/jnci/djv020.
52. Ewald JA, Desotelle JA, Wilding G, DF J. Therapy-induced senes-
cence in cancer. J Natl Cancer Inst. 2010;102:1536–1546.
doi:10.1093/jnci/djq364.
53. DemariaM,O’LearyMN,Chang J, Shao L, Liu S, Alimirah F, Koenig K,
Le C, Mitin N, Deal AM, et al. Cellular senescence promotes adverse
effects of chemotherapy and cancer relapse. Cancer Discov.
2017;7:165–176. doi:10.1158/2159-8290.CD-16-0241.
54. Ohanna M, Cheli Y, Bonet C, Bonazzi VF, Allegra M, Giuliano S,
Bille K, Bahadoran P, Giacchero D, Lacour JP, et al. Secretome from
senescent melanoma engages the STAT3 pathway to favor reprogram-
ming of naive melanoma towards a tumor-initiating cell phenotype.
Oncotarget. 2013;4:2212–2224. doi:10.18632/oncotarget.1143.
55. Yu YC, Yang PM, Chuah QY, Huang YH, Peng CW, Lee YJ,
Chiu SJ. Radiation-induced senescence in securin-deficient cancer
cells promotes cell invasion involving the IL-6/STAT3 and
PDGF-BB/PDGFR pathways. Sci Rep. 2013;3:1675. doi:10.1038/
srep01675.
56. Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M,
Pinton S, Zhang J, Kalathur M, Civenni G, et al. Enhancing
chemotherapy efficacy in Pten-deficient prostate tumors by acti-
vating the senescence-associated antitumor immunity. Cell Rep.
2014;9:75–89. doi:10.1016/j.celrep.2014.08.044.
57. Dahbour S, Jamali F, Alhattab D, Al Radaideh A, Ababneh O, Al
Ryalat N, Al Bdour M, Hourani B, Msallam M, Rasheed M, et al.
Mesenchymal stem cells and conditioned media in the treatment
of multiple sclerosis patients: clinical, ophthalmological and radi-
ological assessments of safety and efficacy. CNS Neurosci Ther.
2017;23:866–874. doi:10.1111/cns.12759.
58. Wang X, Li T, Cheng Y, Wang P, Yuan W, Liu Q, Yang F, Liu Q,
Ma D, Ding S, et al. CYTL1 inhibits tumor metastasis with
decreasing STAT3 phosphorylation. Oncoimmunology. 2019;8:
e1577126. doi:10.1080/2162402X.2019.1577126.
59. Yang H, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y,
Kroemer G. STAT3 inhibition enhances the therapeutic efficacy of
immunogenic chemotherapy by stimulating type 1 interferon
production by cancer cells. Cancer Res. 2015;75:3812–3822.
doi:10.1158/0008-5472.CAN-15-1122.
60. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H,
Fitz LJ, Malenkovich N, Okazaki T, ByrneMC, et al. Engagement of the
PD-1 immunoinhibitory receptor by a novel B7 familymember leads to
negative regulation of lymphocyte activation. J Exp Med.
2000;192:1027–1034. doi:10.1084/jem.192.7.1027.
61. Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D,
Garcia C, Wu Y, Kuhne M, Srinivasan M, et al. In vitro char-
acterization of the anti-PD-1 antibody nivolumab, BMS-936558,
and in vivo toxicology in non-human primates. Cancer Immunol
Res. 2014;2:846–856. doi:10.1158/2326-6066.CIR-14-0040.
62. Sharma P, Allison JP. The future of immune checkpoint therapy.
Science. 2015;348:56–61. doi:10.1126/science.aaa8172.
63. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J,
Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, et al. An
immune-active tumor microenvironment favors clinical response to
ipilimumab. Cancer Immunol Immunother. 2012;61:1019–1031.
doi:10.1007/s00262-011-1172-6.
e1715767-16 M. DE MARTINO ET AL.
